Abstract
The state of the art in research on human gene therapy is summarized. Clinical trials are estimated to be at most three years away for some single gene defects, with current research focused on somatic cell rather than germline therapy. A gene therapy subcommittee of the National Institutes of Health's Recombinant DNA Advisory Committee is drafting guidelines for investigators who are planning to submit their research protocols to the committee for review.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
